You searched for "therapeutics"
New study uncovers key mechanism behind a common genetic cause of age-related visual loss
A groundbreaking study has revealed important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, providing hope for future therapeutic developments, and finding implications for other neurological diseases. FECD is a common,...Worshipful Company of Spectacle Makers awards silver medal to Professor Robert Maclaren
At a Court Lunch held in the historic Apothecaries’ Hall last week, the Worshipful Company of Spectacle Makers awarded its prestigious Silver (Fincham) Medal to Professor Robert MacLaren. Professor MacLaren is Professor of Ophthalmology at the University of Oxford, Consultant...
Developments in Ophthalmology: Ophthalmic Radiation Therapy Techniques and Applications
Radiation was discovered by Wilhelm Roentgen in 1895, and since then has been used to treat a variety of cancers. Its therapeutic properties have been widely used for ocular and periocular tumours and inflammatory disease, but the present era is...Real world data of post-IVT endophthalmitis, from a nurse-delivered intravitreal injection service
Introduction Intravitreal injection of neutralising anti-vascular endothelial growth factor (VEGF) antibody was licenced more than a decade ago, and over the years there has been proportionate increase in the number of intravitreal injections [1]. Injection of a therapeutic agent through...
Amblyopia treatment review
This review paper summarises the main causes and neural mechanisms that characterise amblyopia. The authors analysed neuroanatomical, neurophysiological and electrophysiological studies in the literature to better understand actual treatment regimens and evaluate new therapeutic possibilities. They considered causes of strabismus,...
Two-year GATHER2 data: anatomical gains, functional questions for avacincaptad pegol in geographic atrophy
Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) remains a leading cause of irreversible central vision loss, and complement dysregulation has long been implicated in its pathogenesis. In 2023, the US FDA approved the first two GA therapies, both...Redefining the future of sight - Moorfields Eye Charity launches first major national funding initiative
New grants strategy aims to enable innovation at scale and transform eye health. Moorfields Eye Charity has launched a significant national funding initiative to accelerate the urgent development of new eye health treatments and interventions. The new Discovery and Translation...Conference Report: Retina UK 2025
The Retina UK Annual Conference 2025 took place at the Holiday Inn London in London, UK, on 20 September and was hosted both in-person and online. The event included expert speakers, healthcare professionals, and patients with lived experience with retinal...Moorfields: Ocular emergencies level 1
Designed for optometrists, orthoptists, nurses and other allied ophthalmic health professionals, this module will deliver the knowledge and skills required for the examination, investigation, diagnosis, treatment, and management of patients who present in an ophthalmic emergency setting. Entry requirementsBSc (Hons)...Effect of the COVID-19 Urgent Eyecare Service on patient referrals to general practitioners and Hospital Eye Service
The COVID-19 Urgent Eyecare Services (CUES) was developed to relieve the demands of hospital ophthalmology, aiming to allow patients to have remote consultations and be managed by community optometric practice. This was because access to Hospital Eye Service (HES) Ophthalmic...
Platelet rich fibrin membrane for descemetocele
This case series described the use of a novel technique in the treatment of descemetocele. Three patients developed descemetoceles following infective keratitis with impending risk of corneal perforation. Platelet rich fibrin (PRF) membrane was prepared using 8ml of fresh venous...
